Nul, a telehealth alcohol reduction startup, has raised £740,000 in a seed round led by dmg ventures and BYVP, with participation from a group of angel investors. It provides a service that combines clinical care, prescription medication, digital treatment pathways and behavioural support to help people reduce their alcohol consumption. The funding will support a full UK commercial launch, expansion of its clinical and product teams, scaling customer acquisition and preparation for future international expansion, including the US market.
The service offers a fully remote subscription programme built around naltrexone, a medicine used to reduce alcohol cravings by targeting the brain’s reward pathways. It includes virtual consultations, ongoing clinical support and structured digital guidance based on The Sinclair Method, and is aimed at people who want to cut down gradually using medication- and therapy-supported reduction methods rather than treatment models that require immediate or complete abstinence.
Nul launched a UK test phase in summer 2025 and has onboarded more than 120 paying customers, reaching an annualised revenue run rate of more than £300,000 within its first months, driven largely by organic demand and word of mouth. Alongside the round, it plans to launch a crowdfunding campaign on Republic Europe to allow retail investors to participate.
Telehealth and online pharmacy platforms have transformed categories like weight loss and mental health, yet alcohol has been left behind despite the scale of the problem. Nul is about making evidence-based treatment accessible, discreet and compatible with real life.
